CA3016688A1 - Ophthalmic cross-linking agents and associated methods - Google Patents

Ophthalmic cross-linking agents and associated methods Download PDF

Info

Publication number
CA3016688A1
CA3016688A1 CA3016688A CA3016688A CA3016688A1 CA 3016688 A1 CA3016688 A1 CA 3016688A1 CA 3016688 A CA3016688 A CA 3016688A CA 3016688 A CA3016688 A CA 3016688A CA 3016688 A1 CA3016688 A1 CA 3016688A1
Authority
CA
Canada
Prior art keywords
copper
composition
corneal
ophthalmic
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3016688A
Other languages
English (en)
French (fr)
Inventor
Balamurali K. Ambati
Hironori UEHARA
Santosh MUDDANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA3016688A1 publication Critical patent/CA3016688A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3016688A 2016-03-08 2016-12-06 Ophthalmic cross-linking agents and associated methods Pending CA3016688A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305227P 2016-03-08 2016-03-08
US62/305,227 2016-03-08
PCT/US2016/065215 WO2017155580A1 (en) 2016-03-08 2016-12-06 Cross-linking agents and associated methods

Publications (1)

Publication Number Publication Date
CA3016688A1 true CA3016688A1 (en) 2017-09-14

Family

ID=59790799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3016688A Pending CA3016688A1 (en) 2016-03-08 2016-12-06 Ophthalmic cross-linking agents and associated methods

Country Status (8)

Country Link
US (3) US11065275B2 (https=)
EP (2) EP3426262B1 (https=)
JP (3) JP6929010B2 (https=)
KR (2) KR20250026890A (https=)
AU (2) AU2016396661B2 (https=)
CA (1) CA3016688A1 (https=)
ES (1) ES2959242T3 (https=)
WO (1) WO2017155580A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
ES2986057T3 (es) 2012-03-29 2024-11-08 Epion Therapeutics Inc Composiciones y métodos para tratar o prevenir enfermedades asociadas al estrés oxidativo
US11065275B2 (en) * 2016-03-08 2021-07-20 University Of Utah Research Foundation Cross-linking agents and associated methods
KR20250109788A (ko) * 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
MX2021008821A (es) 2019-01-25 2021-08-24 Avedro Inc Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea.
CA3146848A1 (en) * 2019-07-11 2021-01-14 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療
CN114082960B (zh) * 2021-11-11 2023-01-17 江苏徐工工程机械研究院有限公司 轴套的制备方法、轴套及挖掘机
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490389A (en) * 1976-03-11 1984-12-25 Nelson Research & Development Co. Contact lens preserving solution containing ascorbic acid or salts thereof
WO1991012808A1 (en) * 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US5997911A (en) * 1996-08-27 1999-12-07 Brinton Veterinary Supply, Inc. Composition and method for reducing diarrhea in poultry and swine
JPH10273322A (ja) * 1997-01-30 1998-10-13 Kubota Corp 抗菌性複合チタン酸化合物およびその製造方法
BR9908692A (pt) 1998-03-09 2001-12-04 Ista Pharmaceuticals Inc Uso de agentes de enrijecimento corneal emortocerotologia enzimática
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
CA2431651A1 (en) * 2000-11-16 2002-05-23 Kenneth T. Zeiler Antifungal nail composition and method of use
US7767652B2 (en) * 2004-07-21 2010-08-03 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
WO2006055526A2 (en) * 2004-11-16 2006-05-26 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
US20060165611A1 (en) * 2005-01-26 2006-07-27 National Research Laboratories, Ltd. Composition for Treating and Preventing Periodontal Disease and Method of Use
US20060276777A1 (en) 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
EP2089282B1 (en) 2006-12-07 2014-01-08 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
WO2008124009A2 (en) * 2007-04-02 2008-10-16 The Cleveland Clinic Foundation Treating glaucoma
JP2013506005A (ja) 2009-09-29 2013-02-21 ギリアド バイオロジクス，インク． 眼の繊維症の処置のための方法及び組成物
CN102100693A (zh) * 2009-12-16 2011-06-22 沈阳兴齐制药有限公司 一种含有肌肽的人工泪液及其制备方法
BRPI1002523B1 (pt) * 2010-07-14 2020-06-02 Universidade Federal De Minas Gerais Processo de síntese de complexos de cobre com atividade antitumoral
WO2014065863A1 (en) 2012-10-22 2014-05-01 The Regents Of The University Of California Compositions and methods for promoting collagen-crosslinking
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
DE102014012675A1 (de) 2014-08-26 2016-03-03 Wavelight Gmbh Vernetzung von Augengewebe
CN107530324A (zh) * 2015-04-09 2018-01-02 雷伯瑞特里巴达西公司 用于眼科用途的吡咯烷酮羧酸（pca）
US11065275B2 (en) * 2016-03-08 2021-07-20 University Of Utah Research Foundation Cross-linking agents and associated methods
KR20250109788A (ko) * 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료

Also Published As

Publication number Publication date
AU2023202236A1 (en) 2023-05-04
JP2021185154A (ja) 2021-12-09
JP2019511493A (ja) 2019-04-25
EP4324454A3 (en) 2024-05-01
WO2017155580A1 (en) 2017-09-14
AU2016396661B2 (en) 2023-01-19
ES2959242T3 (es) 2024-02-22
US20210322470A1 (en) 2021-10-21
JP2023153926A (ja) 2023-10-18
KR102771170B1 (ko) 2025-02-24
EP3426262B1 (en) 2023-08-23
AU2023202236B2 (en) 2025-05-29
EP3426262C0 (en) 2023-08-23
KR20250026890A (ko) 2025-02-25
US20190083529A1 (en) 2019-03-21
US11065275B2 (en) 2021-07-20
KR20180119654A (ko) 2018-11-02
EP4324454A2 (en) 2024-02-21
US20260041714A1 (en) 2026-02-12
EP3426262A4 (en) 2019-10-16
EP3426262A1 (en) 2019-01-16
JP6929010B2 (ja) 2021-09-01
AU2016396661A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
AU2023202236B2 (en) Cross-linking agents and associated methods
US12544400B2 (en) Treatment of myopic progression
AU2026201640A1 (en) Multi-agent ocular formulations and treatment methods
HK40107891A (en) Cross-linking agents and associated methods
US20240122974A1 (en) Treatment of myopia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240703

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240829

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20241107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251212

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20251212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129